1 Department of Pediatric and Gastrointestinal Surgery, Ghent University Hospital, Ghent, Belgium.
2 Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Fontenay-aux-Roses, France.
Cell Transplant. 2017 Dec;26(12):1919-1930. doi: 10.1177/0963689717721515.
Cancer patients treated with radiotherapy (RT) could develop severe late side effects that affect their quality of life. Long-term bowel complications after RT are mainly characterized by a transmural fibrosis that could lead to intestinal obstruction. Today, surgical resection is the only effective treatment. However, preoperative RT increases the risk of anastomotic leakage. In this study, we attempted to use mesenchymal stromal cells from adipose tissue (Ad-MSCs) to improve colonic anastomosis after high-dose irradiation. MSCs were isolated from the subcutaneous fat of rats, amplified in vitro, and characterized by flow cytometry. An animal model of late radiation side effects was induced by local irradiation of the colon. Colonic anastomosis was performed 4 wk after irradiation. It was analyzed another 4 wk later (i.e., 8 wk after irradiation). The Ad-MSC-treated group received injections several times before and after the surgical procedure. The therapeutic benefit of the Ad-MSC treatment was determined by colonoscopy and histology. The inflammatory process was investigated using Fluorine-182-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography and Computed Tomography (F-FDG-PET/CT) imaging and macrophage infiltrate analyses. Vascular density was assessed using immunohistochemistry. Results show that Ad-MSC treatment reduces ulcer size, increases mucosal vascular density, and limits hemorrhage. We also determined that 1 Ad-MSC injection limits the inflammatory process, as evaluated through F-FDG-PET-CT (at 4 wk), with a greater proportion of type 2 macrophages after iterative cell injections (8 wk). In conclusion, Ad-MSC injections promote anastomotic healing in an irradiated colon through enhanced vessel formation and reduced inflammation. This study also determined parameters that could be improved in further investigations.
接受放射治疗 (RT) 的癌症患者可能会出现严重的晚期副作用,影响他们的生活质量。RT 后长期的肠道并发症主要表现为贯穿肠壁的纤维化,这可能导致肠梗阻。目前,手术切除是唯一有效的治疗方法。然而,术前 RT 会增加吻合口漏的风险。在这项研究中,我们试图使用脂肪组织来源的间充质基质细胞 (Ad-MSCs) 改善高剂量照射后结肠吻合口。MSCs 从大鼠皮下脂肪中分离出来,在体外扩增,并通过流式细胞术进行鉴定。通过局部照射结肠诱导晚期放射副作用动物模型。照射后 4 周进行结肠吻合术。然后在 4 周后(即照射后 8 周)进行分析。Ad-MSC 治疗组在手术前后多次接受注射。通过结肠镜检查和组织学来确定 Ad-MSC 治疗的治疗效果。使用氟-18-2-氟-2-脱氧-d-葡萄糖正电子发射断层扫描和计算机断层扫描 (F-FDG-PET/CT) 成像和巨噬细胞浸润分析研究炎症过程。通过免疫组织化学评估血管密度。结果表明,Ad-MSC 治疗可减少溃疡面积、增加黏膜血管密度并限制出血。我们还确定,1 次 Ad-MSC 注射可限制炎症过程,如通过 F-FDG-PET-CT(在 4 周时)评估,通过迭代细胞注射后(8 周),2 型巨噬细胞的比例更高。总之,Ad-MSC 注射通过增强血管形成和减少炎症促进照射结肠的吻合口愈合。本研究还确定了在进一步研究中可以改进的参数。